International Assets Investment Management LLC acquired 241,080 shares of Gilead Sciences, Inc., following the company’s announcement of strong third-quarter 2026 results. The results surpassed analyst expectations.
Gilead’s base business sales rose 16% year over year, largely driven by its HIV and oncology products. Sales of Biktarvy, the company’s flagship HIV treatment, increased 10% year over year. Revenue for cancer drug Trodelvy rose 41.7%.
Gilead raised its full-year 2026 product sales guidance to $31.0 billion to $31.3 billion.